Vaxcyte, Inc. PCVX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s cash & equivalents?
- Vaxcyte, Inc. (PCVX) reported cash & equivalents of $262.31M in Q1 2026.
- How has Vaxcyte, Inc.'s cash & equivalents changed year-over-year?
- Vaxcyte, Inc.'s cash & equivalents decreased by 24.7% year-over-year, from $348.17M to $262.31M.
- What is the long-term trend for Vaxcyte, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s cash & equivalents has grown at a -14.6% compound annual growth rate (CAGR), from $386.2M to $175.43M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.